Molecular therapy via transcriptional regulation with double-stranded oligodeoxynucleotides as decoys.
The number of reports on in vivo gene therapies with decoy ODNs complexed with HVJ liposomes has recently increased. Diligent efforts to improve HVJ vectors as gene carriers and to expand the therapeutic applications of NFkB and E2F decoy ODNs will be important for the improved treatment of many genetic diseases.
Nakamura
Hiroshige
H
Division of Gene Therapy Science, Graduate School of Medicine, Osaka University Medical School, Yamada-oka 2-2, Suita, Osaka 565-0871, Japan. kaneday@gts.med.osaka-u.ac.jp
Morishita
Ryuichi
R
Kaneda
Yasufumi
Y
D000818:Animals; D018797:Cell Cycle Proteins; D016384:Consensus Sequence; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008081:Liposomes; D016328:NF-kappa B / Q000235:genetics; D009841:Oligonucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D014157:Transcription Factors / Q000235:genetics*; D014158:Transcription, Genetic; D014162:Transfection
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D008081:Liposomes; D016328:NF-kappa B; D009841:Oligonucleotides; D014157:Transcription Factors